Successful treatment of paraneoplastic pemphigus and bronchiolitis obliterans associated with follicular lymphoma with obinutuzumab and bendamustine

Curr Probl Cancer. 2022 Apr;46(2):100813. doi: 10.1016/j.currproblcancer.2021.100813. Epub 2021 Nov 19.

Abstract

We herein report the rare case of a 72-year-old female who presented with paraneoplastic pemphigus (PNP) and bronchiolitis obliterans (BO) associated with follicular lymphoma (FL), who was successfully treated with obinutuzumab (GA101; G) and bendamustine (B). The patient had severe erosive stomatitis and bilateral conjunctival hyperemia that persisted for more than 6 months. A huge mass was found in the abdominal cavity, and a biopsy revealed grade 1 FL (stage IV). Based on a lip biopsy result, the patient was diagnosed with PNP associated FL. The patient received bendamustine and obinutuzumab (BG) chemotherapy and FL and PNP responded very well, but BO was additionally associated during the course of BG. BO progressed without exacerbation as BG therapy progressed to a 2 year maintenance therapy with G, and combination of azithromycin, inhaled bronchodilator therapy, and corticosteroid. She was followed up at the outpatient department with no pulmonary function decline or FL and PNP recurrence. Our case suggests that BG could be a promising treatment option for PNP and BO.

Keywords: Bendamustine; Bronchiolitis obliterans; Follicular lymphoma; Obinutuzumab; Paraneoplastic pemphigus.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antibodies, Monoclonal, Humanized
  • Bendamustine Hydrochloride / therapeutic use
  • Bronchiolitis Obliterans* / complications
  • Bronchiolitis Obliterans* / drug therapy
  • Female
  • Humans
  • Lymphoma, Follicular* / complications
  • Lymphoma, Follicular* / diagnosis
  • Lymphoma, Follicular* / drug therapy
  • Paraneoplastic Syndromes* / complications
  • Paraneoplastic Syndromes* / etiology
  • Pemphigus* / complications
  • Pemphigus* / drug therapy

Substances

  • Antibodies, Monoclonal, Humanized
  • Bendamustine Hydrochloride
  • obinutuzumab